secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001808805-24-000004
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology reports FY2023 net loss $63.7M; cash runway into H2 2026
-------------------------------------------------------------------------------

- Net loss $63.7M for FY2023, compared to $57.9M in FY2022; operating expenses $76.2M, up 20% YoY.
- Cash, equivalents and investments $264.1M as of Dec 31, 2023; expected runway into second half 2026.
- FY2024 operating expense expected to grow ~25% vs 2023.
- Platform launch (instruments, consumables, software) planned for 2025.
- CEO Sujal Patel cited fiscal discipline and progress on proprietary proteome analysis platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/0001808805-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/naut-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001808805-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer